Real-world evidence for non-valvular atrial fibrillation patients treated with oral anticoagulation in the Nordics

The purpose is to compare OAC naive patients commencing treatment with reduced dose NOAC compared to those initiating warfarin, to describe the risk of cardiovascular events including ischemic stroke/systemic embolism, intracranial hemorrhage, fatal bleeding, and other events such as kidney failure and acute kidney injury.

Lupaan tehdyt muutokset: Voimassaolon jatkaminen; Käsittelijöiden muuttaminen

Alkuperäisen luvan myöntäjä: Kela, Tilastokeskus